INT256014

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2008
Last Reported 2008
Negated 0
Speculated 1
Reported most in Body
Documents 1
Total Number 4
Disease Relevance 0.64
Pain Relevance 0.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Lnpep) plasma membrane (Lnpep) intracellular (Lnpep)
cytoplasm (Lnpep)
Lnpep (Mus musculus)
Pain Link Frequency Relevance Heat
Onset of action 4 94.18 High High
antagonist 24 90.16 High High
long-term potentiation 4 65.12 Quite High
Enkephalin 4 63.20 Quite High
Hippocampus 12 60.56 Quite High
Eae 8 58.80 Quite High
Dopamine 8 54.16 Quite High
Thalamus 8 34.16 Quite Low
antidepressant 4 24.16 Low Low
Locus ceruleus 4 23.28 Low Low
Disease Link Frequency Relevance Heat
Cognitive Disorder 124 97.00 Very High Very High Very High
Targeted Disruption 8 87.76 High High
Sprains And Strains 32 51.20 Quite High
Obesity 4 48.64 Quite Low
Anxiety Disorder 8 34.40 Quite Low
Hypertension 16 5.00 Very Low Very Low Very Low
Aging 4 5.00 Very Low Very Low Very Low
Myocardial Infarction 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
To summarise the argument: the AT4 receptor and IRAP have identical binding properties for angiotensin IV, and expression of the cDNA for IRAP gives rise to a protein with the binding characteristics of the AT4 receptor.
IRAP Binding (binding) of
1) Confidence 0.31 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0 Pain Relevance 0
If angiotensin IV produces its effects via interaction with IRAP and oxytocin, a similar pattern of effects might therefore be seen.
IRAP Binding (interaction) of
2) Confidence 0.31 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.27 Pain Relevance 0.07
The salient points of their argument are: the effects of enzyme inhibition and accumulation of endogenous peptides are slow, in the order of hours or days, whilst the onset of action of angiotensin IV in some tissues is within seconds; the concentrations of angiotensin IV required to produce biological, that is, cognitive effects, are well below the concentrations required to inhibit IRAP; and there is dispute as to whether angiotensin IV is a competitive substrate of IRAP or whether it binds allosterically.
IRAP Spec (whether) Binding (binds) of associated with cognitive disorder and onset of action
3) Confidence 0.31 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.18 Pain Relevance 0.16
The compromise suggested by Wright and Harding [6] is that angiotensin IV binds to IRAP, its cognate receptor, but that there is some other transduction mechanism not reliant on inhibition of the enzyme.
IRAP Binding (binds) of
4) Confidence 0.29 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604899 Disease Relevance 0.19 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox